News Detail
New Delhi, 01 Oct 2024: Based on research conducted at Central Drug Research Institute (CDRI), Lucknow and data from antibody-based therapies (biologics), a protein Sclerostin, has emerged as a promising drug target for treating Chronic kidney disease (CKD) induced osteoporosis a......
View Details
Source : PIB
CDRI
antibody-based therapies (biologics)
protein Sclerostin
Chronic kidney disease (CKD)
postmenopausal osteoporosis
Related News
- MBBS from abroad, started practicing medicine without passing FMGE, Registrations cancelled (08-11-2024)
- CM Flying raid on medicine shop in Sonipat, Chemist used to keep banned medicines in car (08-11-2024)
- One died, two serious after consuming Homeopathic medicine given by a quack, arrested (08-11-2024)
- DCA seizes ayurvedic medicine for misleading claims (08-11-2024)
- More cases against Ramdev, Acharya Balkrishna in Kerala (08-11-2024)
- India's Nutraceutical Sector Eyes Global Leadership with Strategic Policy Push (08-11-2024)
- Kerala launches campaign against misuse of antibiotics (08-11-2024)
- NCS Impounds 16 Containers of Illegal Drugs from India, UK, Canada (08-11-2024)
- US FDA proposes ending use of decongestant Phenylephrine (08-11-2024)
- Overpriced antibiotic ointment seized by DCA officials in Hyderabad (07-11-2024)